Giehler, F. ; Ostertag, M.S. ; Sommermann, T.* ; Weidl, D.* ; Sterz, K. ; Kutz, H. ; Moosmann, A. ; Feller, S.M.* ; Geerlof, A. ; Biesinger, B.* ; Popowicz, G.M. ; Kirchmair, J.* ; Kieser, A.
Epstein-Barr virus-driven B cell lymphoma mediated by a direct LMP1-TRAF6 complex.
Nat. Commun. 15:414 (2024)
Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) drives viral B cell transformation and oncogenesis. LMP1’s transforming activity depends on its C-terminal activation region 2 (CTAR2), which induces NF-κB and JNK by engaging TNF receptor-associated factor 6 (TRAF6). The mechanism of TRAF6 recruitment to LMP1 and its role in LMP1 signalling remains elusive. Here we demonstrate that TRAF6 interacts directly with a viral TRAF6 binding motif within CTAR2. Functional and NMR studies supported by molecular modeling provide insight into the architecture of the LMP1-TRAF6 complex, which differs from that of CD40-TRAF6. The direct recruitment of TRAF6 to LMP1 is essential for NF-κB activation by CTAR2 and the survival of LMP1-driven lymphoma. Disruption of the LMP1-TRAF6 complex by inhibitory peptides interferes with the survival of EBV-transformed B cells. In this work, we identify LMP1-TRAF6 as a critical virus-host interface and validate this interaction as a potential therapeutic target in EBV-associated cancer.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Nf-kappa-b; Membrane-protein 1; Receptor-associated Factor-3; Terminal Kinase Pathway; Latent Membrane-protein-1; Binding-site; Traf-binding; Growth Transformation; Signal-transduction; Critical Regulator
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2024
Prepublished im Jahr
0
HGF-Berichtsjahr
2024
ISSN (print) / ISBN
2041-1723
e-ISSN
2041-1723
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 15,
Heft: 1,
Seiten: ,
Artikelnummer: 414
Supplement: ,
Reihe
Verlag
Nature Publishing Group
Verlagsort
London
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
POF Topic(s)
30203 - Molecular Targets and Therapies
Forschungsfeld(er)
Enabling and Novel Technologies
Immune Response and Infection
PSP-Element(e)
G-509800-004
G-503000-001
G-501500-001
Förderungen
Deutsches Zentrum für Infektionsforschung (German Center for Infection Research)
Deutsche Forschungsgemeinschaft (German Research Foundation)
Copyright
Erfassungsdatum
2024-01-16